Hormonal
Tirzepatide utilization has rapidly displaced other glucose- and weight-lowering medications in the US, with its uptake being steeper and more sustained than previous GLP-1 receptor agonists.
Tirzepatide is currently the fastest-growing and most prescribed glucose- and weight-lowering medication in the US, rapidly replacing older drugs like metformin and other GLP-1s. If you have T2D or obesity, this drug is becoming the standard of care, but access may be difficult due to shortages. Prioritize securing a prescription early if eligible.
Tirzepatide uptake was more rapid and sustained compared with initial post-approval periods for other medications.
Why this rating
Large population-based cohort study (n > 1.8 million) with robust claims data, though observational.
Source
Trends in Utilization of Glucose- and Weight-Lowering Medications After Tirzepatide Approval in the United States
John W. Ostrominski et al. · Annals of Internal Medicine · 2025
DOI 10.7326/annals-24-02870
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →